FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	DC	20549

STATEMENT	OF (CHANGES	IN BENEF	ICIAL (OWNERSHIP

OMB APPROVAL								
OMB Number: 3235-0287								
Estimated average burden								
hours per response.	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

	1. Name and Address of Reporting Person* 2. Issuer Name and Ticker or Trading Symbol Editas Medicine, Inc. [EDIT]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner											
(Last) C/O EDI 11 HURI	TAS MED	First)	(Middle)		3. Date of Earliest Transaction (Month/Day/Year) 06/02/2022					X	Officer (since title			Other (s below)	pecify			
(Street) CAMBR			02141		4. If Amendment, Date of Original Filed (Month/Day/Year)					6. Ind Line)								
(City) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
1. Title of Security (Instr. 3)			2. Transac Date			ned n Date,	3. Transa Code (I	ction	4. Securities Acquired (A Disposed Of (D) (Instr. 3,		red (A)	or 5. Amount of		lly	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Common Start (II)			06/02/7	2/2022			Code	V	(D)		_	s ₀	Transaction (Instr. 3 and	Transaction(s) (Instr. 3 and 4)				
Common	Common Stock ⁽¹⁾ 06/02/2022																	
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	ercise (Month/Day/Year) of ative	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	saction (Instr.	Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amou of Securities Underlying Derivative Securi (Instr. 3 and 4)		Derivative Security		9. Number of derivative Securities Beneficially Owned Following Reported		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)		Date Exercisabl		xpiration ate	Title	Amor or Numl of Sh	ber		Transaction(s) (Instr. 4)			
Stock Option (right to buy)	\$11.54	06/02/2022		A		950,209		(2)	00	5/01/2032	Common Stock	950,	,209	\$0	950,209		D	

Explanation of Responses:

- 1. The common stock received by the Reporting Person was in connection with the grant of a restricted stock unit award to the Reporting Person, for no consideration, and which is scheduled to vest over four years in equal yearly installments of one-fourth of the shares, with the first such installment to vest on June 2, 2023 continuing through June 2, 2026.
- 2. This option was granted on June 2, 2022 and is scheduled to vest over four years, with 25% of the shares scheduled to vest on June 2, 2023 and the remaining 75% of the shares scheduled to vest in equal monthly installments thereafter through June 2, 2026.

/s/ Gilmore O'Neill

06/06/2022

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.